Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Vinflunine in the treatment of bladder cancer

Authors Mark Bachner, Maria De Santis

Published 5 December 2008 Volume 2008:4(6) Pages 1243—1253

DOI https://doi.org/10.2147/TCRM.S3384

Review by Single-blind

Peer reviewer comments 3

Mark Bachner, Maria De Santis

3rd Medical Department – Center for Oncology and Hematology, Kaiser Franz Josef-Spital der Stadt Wien, and Ludwig Boltzmann-Institute for Applied Cancer Research Vienna (LBI-ACR VIEnna), Cluster Translational Oncology, Kaiser Franz Josef-Spital der Stadt Wien, and Applied Cancer Research – Institution for Translational Research Vienna (ACR-ITR VIEnna)/CEADDP, Vienna, Austria

Abstract: Vinflunine (VFL) is a third-generation bifluorinated semi-synthetic vinca alkaloid obtained by superacidic chemistry from its parent compound, vinorelbine. As with the other vinca alkaloids, the main antineoplastic effects of VFL arise from its interaction with tubulin, the major component of microtubules in mitotic spindles. In contrast to other vinca alkaloids, VFL shows some distinctive properties in terms of tubulin binding, possibly explaining its superior antitumor activity in vitro and in vivo compared with vinorelbine as well as its excellent safety profile. In transitional cell carcinoma (TCC), two single-agent phase II trials were performed testing VFL in platinum-pretreated patients, showing moderate response rates and promising disease control rates. Therefore, the first phase III trial in modern times for second-line TCC of the urothelium was designed in order to further investigate the activity of VFL. First results were presented at the 2008 ASCO conference. VFL appears to be a possible treatment option for patients with TCC progressing after first-line platinum-containing chemotherapy.

Keywords: vinflunine, transitional cell carcinoma (TCC) of the bladder, bladder cancer, chemotherapy, second-line chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

The influence of comorbid personality disorders on recovery from depression

Wongpakaran T, Wongpakaran N, Boonyanaruthee V, Pinyopornpanish M, Intaprasert S

Neuropsychiatric Disease and Treatment 2015, 11:725-732

Published Date: 16 March 2015

Tissue inhibitor of matrix metalloproteinases-1 loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood–brain barrier

Chaturvedi M, Molino Y, Sreedhar B, Khrestchatisky M, Kaczmarek L

International Journal of Nanomedicine 2014, 9:575-588

Published Date: 20 January 2014

Responsiveness of voltage-gated calcium channels in SH-SY5Y human neuroblastoma cells on quasi-three-dimensional micropatterns formed with poly (l-lactic acid)

Wu ZZ, Wang ZW, Zhang LG, An ZX, Zhong DH, Huang QP, Luo MR, Liao YJ, Jin L, Li CZ, Kisaalita WS

International Journal of Nanomedicine 2013, 8:93-107

Published Date: 3 January 2013

Enhanced cellular uptake of aminosilane-coated superparamagnetic iron oxide nanoparticles in mammalian cell lines

Zhu XM, Wang YX, Leung KCF, Lee SF, Zhao F, Wang DW, Lai JMY, Wan C, Cheng CHK, Ahuja AT

International Journal of Nanomedicine 2012, 7:953-964

Published Date: 21 February 2012

Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling

Wessen Maruwge, Pádraig D’Arcy, Annika Folin, Slavica Brnjic, Johan Wejde, et al

OncoTargets and Therapy 2008, 1:67-78

Published Date: 27 November 2008

The influence of polymorbidity, revascularization, and wound therapy on the healing of arterial ulceration

Joerg Tautenhahn, Ralf Lobmann, Brigitte Koenig, Zuhir Halloul, Hans Lippert, Thomas Buerger

Vascular Health and Risk Management 2008, 4:683-689

Published Date: 6 June 2008

Obstructive sleep apnea - management update

Craig A Hukins

Neuropsychiatric Disease and Treatment 2006, 2:309-326

Published Date: 15 September 2006